Table 3Base-case results

StrategyLife Expectancy (year)CostQALYsICER (cost per QALY)
TotalIncrementalTotalIncrementalTotalIncremental
Staged3.80£31,749-3.22--
Simultaneous4.300.51£29,282 -£2,467 3.51 0.28 Dominant

ICER: incremental cost-effectiveness ratio; QALYs: quality-adjusted life years

From: Treatment for metastatic colorectal cancer in the liver amenable to treatment with curative intent

Cover of Treatment for metastatic colorectal cancer in the liver amenable to treatment with curative intent
Treatment for metastatic colorectal cancer in the liver amenable to treatment with curative intent: Colorectal cancer (update): Evidence review D2a.
NICE Guideline, No. 151.
National Guideline Alliance (UK).
Copyright © NICE 2020.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.